Introduction
============

Virgin female moths attract conspecific males using sex pheromone for species-specific mating. Pheromone biosynthesis and emission from the pheromone gland are activated during a calling period that is synchronized with the photoperiodic cycle through the function of pheromone biosynthesis-activating neuropeptide (PBAN), which is produced in the subesophageal ganglion (Kitamura et al., [@B17]; Raina et al., [@B27]; Raina, [@B28]; Rafaeli, [@B26]). In *Bombyx mori*, PBAN consists of 33 amino acid residues and contains as its active core a C-terminal FXPRLamide motif (X = S, T, G, or V) that is essential for PBAN activity (Kuniyoshi et al., [@B19]).

Several neuropeptides containing the FXPRLamide motif at the C-terminus have been identified from a number of insect orders including Lepidoptera, Diptera, and Orthoptera (Predel and Wegener, [@B25]). These peptides have been reported to regulate various biological activities such as initiation of *B. mori* embryonic diapause (Imai et al., [@B10]) and heliothine pupal (Xu and Denlinger, [@B33]), melanization of larvae in lepidopteran species (Matsumoto et al., [@B22]), hindgut/oviduct contraction in the cockroach and the locust (Nachman et al., [@B23]; Schoofs et al., [@B29]), and acceleration of pupariation in several flies (Zdarek et al., [@B35]). Moreover, PRX or RXamide (X = F, L, V, or Y) peptides have also been identified in many organisms as biologically active peptides (Predel and Wegener, [@B25]; Walker et al., [@B31]). These peptides have been widely identified from insect species (Baggerman et al., [@B1]; Hummon et al., [@B9]; Hauser et al., [@B6]; Weaver and Audsley, [@B32]). The presence of a C-terminal amide and an Arg residue at the second position from the C-terminus, termed the C2 position, in so many diverse insect neuropeptides suggests some functional importance.

The receptors for many of the peptides discussed above have been identified as G protein-coupled receptors (GPCRs). The insect GPCRs have been identified using cultured cells such as HEK293, CHO mammalian cells (Iversen et al., [@B11]; Yamanaka et al., [@B34]), and Sf9 insect cells (Choi et al., [@B4]; Hull et al., [@B8]). The PBAN receptor (PBANR) was first cloned from the corn earworm, *Helicoverpa zea*, as a homolog of the neuromedin U receptor (NmUR) in vertebrates that recognized FXPRNamide peptides (Fujii et al., [@B5]; Choi et al., [@B4]). Since then, PBANRs have been identified as class-A GPCR family members from *B. mori*, *Heliothis virescens*, *Manduca sexta*, and *Plutella xylostella* (Hull et al., [@B8]; Kim et al., [@B15]; Lee et al., [@B20]). In *B. mori*, PBAN binding has been shown *in vitro* using isolated pheromone glands to trigger an influx of extracellular Ca^2+^ in the pheromone producing cells (Mastumoto, [@B21]), as well as insect cells transiently expressing PBANR (Choi et al., [@B4]; Hull et al., [@B8]).

In the course of our study on the structure--activity relationship of PBAN and search for PBAN antagonists to control pests and to obtain a *B. mori* PBANR (BomPBANR)/ligand complex appropriate for crystallographic structural analysis, we established an *in vitro* PBAN assay system by observing Ca^2+^ influx into Sf9 cells, which had been prepared from immature ovaries of *Spodoptera frugiperda* (Vaughn et al., [@B30]), constitutively expressing BomPBANR--EGFP (Hull et al., [@B7]; Kawai et al., [@B13]). We first focused on the C6 residue and determined that a syntheticY^C6^N \[SKTRNFSPRLamide\] was a partial agonist (Kawai et al., [@B12]). Next, we prepared cyclic peptides, cycloY^C6^ \[cyclo(TCYFSPRL)\] and cycloN^C6^ \[cyclo(TCNFSPRL)\], from linear precursor peptides fused to an intein protein (Kimura et al., [@B16]) and determined that these partial peptides were also partial agonists (Kawai et al., [@B13]). These results showed that BomPBANR recognizes the amino acid residue at C6 position and type I β-turn secondary structure (Nachman et al., [@B24]). We also synthesized and examined a peptide substituted with [d]{.smallcaps}-Phe at C4 position \[RYFdFPRLamide, LA-4\] which had been reported as a linear antagonist (Zeltser et al., [@B36]; Ben-Aziz et al., [@B3]) and demonstrated that LA-4 was a partial agonist to BomPBANR (Kawai et al., [@B14]).

In this study, we focused on the Arg residue at the C2 position in the PBAN active core, because this residue is highly conserved in not only PBAN but also many other related neuropeptides. We synthesized four PBAN analogs consisting of 10 amino acid residues, in which the Arg residue was substituted with Ala, Asp, Ser, or [l]{.smallcaps}-2-aminooctanoic acid (Aoc), and assessed their *in vitro* PBAN-like activities by a Ca^2+^ imaging assay using stably transformed Sf9 cells expressing BomPBANR--EGFP and a confocal laser scanning microscope.

Results
=======

Agonistic activities of synthetic PBAN C-terminal peptides
----------------------------------------------------------

To investigate the effect of the Arg side chain on *in vitro* PBAN-like activity, we prepared four synthetic PBAN analogs, in which the Arg residue at the C2 position was substituted with amino acid residues exhibiting different side chain properties (Figure [1](#F1){ref-type="fig"}A). For this purpose, we selected Ala, Asp, Ser, and Aoc for the following reasons: Ala has a simple small side chain that lacks a functional group, Asp has a negatively charged carboxyl group, Ser has a hydroxyl group with an uncharged polarity, while the Aoc side chain is similar in length to the Arg side chain but lacks any functional groups. To determine the agonistic activities of the Ala (R^C2^A), Asp (R^C2^D), Ser (R^C2^S), and Aoc (R^C2^Aoc) analogs, we compared the Ca^2+^ response of the respective analogs with a corresponding PBAN analog composed of the C-terminal 10 residues (PBAN C10). Sf9 cells stably expressing BomPBANR--EGFP were loaded with Fura Red--AM, a fluorescent Ca^2+^ indicator, and their fluorescent profile in response to the each ligand was examined with a confocal laser scanning microscope (Kawai et al., [@B13]). As shown in Figure [1](#F1){ref-type="fig"}B, the PBAN-like activities of all of the R^C2^X peptides were much lower than that of PBAN C10 at 1 nM. R^C2^A and R^C2^D showed full PBAN-like activity at 100 nM, while R^C2^S and R^C2^Aoc showed full activity at 10 nM.

![**Pheromone biosynthesis-activating neuropeptide-like activities of R^C2^X peptides**. **(A)** Amino acid sequences of the R^C2^X peptides. **(B)** Dose dependency of PBAN-like effects of the R^C2^X peptides measured via a Ca^2+^ imaging technique with Fura Red as the Ca^2+^ indicator. Bars represent the mean + SD of five replicates. Different letters (a and b) indicate significant difference at *P* \< 0.05 by the Tukey--Kramer test.](fendo-03-00042-g001){#F1}

Examination of antagonistic activities of R^C2^X peptides
---------------------------------------------------------

Because R^C2^A and R^C2^D showed lower PBAN-like activities than the other two mutations, we also examined their antagonistic activities against PBAN C10.We found that the activity of PBAN C10 at 1 nM decreased to 87 and 85% following the addition of a 10-fold concentration of R^C2^A and R^C2^D, respectively (Figure [2](#F2){ref-type="fig"}), although this reduction in activity was not statistically significant.

![**Antagonistic effects of R^C2^A and R^C2^D**. Effects were measured using the Ca^2+^ imaging technique with Fura Red as the Ca^2+^ indicator. PBAN C10 was added after the addition of R^C2^A and R^C2^D. Bars represent the mean + SD of five replicates.](fendo-03-00042-g002){#F2}

Fluorescent binding assay
-------------------------

To confirm the binding of the R^C2^X mutations to BomPBANR--EGFP, we prepared fluorescent analogs of the synthetic peptides via conjugation with Rhodamine Red-X succinimidyl ester. As before, we used Sf9 cells stably expressing BomPBANR--EGFP to examine binding of each labeled peptide, Sf9 cells were imaged using a confocal laser scanning microscope using excitation at 488 and 560 nm for EGFP and Rhodamine Red-X, respectively. The binding intensity was assessed by the fluorescence ratio of Rhodamine Red-X to EGFP. Figure [3](#F3){ref-type="fig"} shows the results. The expression of BomPBANR--EGFP on the cell surface was visualized as a ring of green fluorescence by EGFP in all cases. It was clearly demonstrated that PBAN C10 bound to BomPBANR--EGFP as observed as a red fluorescent ring on the cell surface, which was merged with green fluorescence to be yellow. However, the binding of the R^C2^X peptides to BomPBANR--EGFP could not be detected clearly.

![**Confocal imaging of BomPBANR**--**EGFP expressing Sf9 cells after incubation with synthetic peptides labeled with Rhodamine Red-X**. Each fluorescence labeled peptide was added at a final concentration of 100 nM. Co-localization is indicated by yellow in the merged images.](fendo-03-00042-g003){#F3}

Discussion
==========

Neuropeptides mediate various biological events in both vertebrates and invertebrates. Among them, there is a group of neuropeptides that share chemical characteristics of C-terminal amidation and the presence of Arg at the C2 position. PBAN, an insect neuropeptide, belongs to this group. In this study, we sought to clarify the role of the Arg residue in PBAN activity. Instead of an ordinary *in vivo* PBAN assay using female moths, we adopted a bioassay assessing PBAN-like activity *in vitro* by using insect (Sf9) cells artificially expressing BomPBANR--EGFP, which we have previously established (Mastumoto, [@B21]; Kawai et al., [@B13]). We synthesized and examined four synthetic peptides, in which Arg at the C2 position was replaced by each of four representative amino acid residues with different chemical properties from Arg.

The activity of R^C2^A was significantly lower than PBAN C10, which is consistent with previous results demonstrating the effect of Ala substitutions of this position in a *Heliothis virescens* PBAN C-terminal hexapeptide (Kim et al., [@B15]). It has also been reported that the substitution of Arg at the C2 position of neuropeptide Y, a vertebrate neuropeptide, with Ala reduced the affinity to both human Y~1~ and Y~2~ receptors (Beck-Sickinger et al., [@B2]). In addition, the reduced *in vivo* PBAN activity was reported following Gln, Lys, or norvaline substitution of Arg at the C2 position in *B. mori* (Kuniyoshi et al., [@B18]). While these results suggest the potential importance of the Arg guanidine group, the length of the side chain may also influence the activity. We consequently prepared a peptide with Aoc at the C2 position because Aoc has a side chain of similar length to Arg but without any functional groups, thus making it hydrophobic. Unexpectedly, the R^C2^Aoc peptide, showed higher activity than R^C2^A (Figure [1](#F1){ref-type="fig"}B). While the guanidino functional group is important for binding, it is apparent that the length of the side chain is also important.

Concerning the hydrophilicity of the side chain, we compared the activity of R^C2^A with that of R^C2^S. R^C2^S was found to be more active than R^C2^A, indicating some contribution of the hydroxyl group. However, the increased bulkiness of the Ser hydroxymethyl group over the Ala methyl group may also contribute to some extent. R^C2^S was a little less active than R^C2^Aoc, indicating the side chain length is more important than hydrophilicity. R^C2^D, which carried a charge opposite to the natural peptide, showed activity stronger than R^C2^A, but was weaker than R^C2^S, indicating that a negative charge is not preferable for binding to the receptor.

Neither R^C2^A nor R^C2^D was able to inhibit the activity of 1 nM PBAN C10 even at a 10-fold higher concentration (10 nM), at which concentration that R^C2^A and R^C2^D exhibited almost no and very low agonistic activity, respectively. This result suggests that both R^C2^A and R^C2^D bind very weakly to BomPBANR; it is unlikely that they bind BomPBANR as strongly as PBAN C10 but cannot trigger the Ca^2+^ influx. The weak binding of the four synthetic analogs was directly demonstrated by observation of the Rhodamine Red-labeled conjugates. We therefore concluded that the Arg residue at C2 position is important for PBANR binding. Although the four mutants exhibited PBAN-like activity comparable to PBAN C10 at 100 nM, we failed to observe any binding at that concentration, perhaps because the Rhodamine Red-labeled analogs were weakly bound and removed during the final washing steps prior to imaging. It is unlikely that the Rhodamine Red-labeled analogs have lower activity than non-labeled peptides, because the possible labeling sites are the ε-amino group of Lys at the C9 position and the N-terminal amino group, which are far from the active core. Experiments at higher concentrations of labeled peptides will be needed.

Materials and Methods
=====================

Synthesis and purification of peptides
--------------------------------------

Pheromone biosynthesis-activating neuropeptide analogs were synthesized with an automated peptide synthesizer Apex 369 (AAPPTec, Louisville, KY, USA) using the Fmoc solid-phase strategy according to the manufacturer's instructions. The Arg residue at the C9 position of all PBAN analogs was replaced with Lys for labeling with Rhodamine Red-X succinimidyl ester. After deprotection and cleavage from the resin, synthetic peptides were purified by HPLC with a PEGASIL ODS column (10 i.d. × 150 mm, Senshu Kagaku, Tokyo, Japan) using two solvents, 0.05% trifluoroacetic acid (TFA; solvent A) and 90% CH~3~CN/0.05% TFA (solvent B). Peptides were eluted at a flow rate of 4.0 ml/min using a step-gradient program starting from 0% B in 2.5 min, then to 75% B in 15 min, and then 100% B over the next 30 min. Reagents for peptide synthesis were purchased from WATANABE CHEMICAL IND., LTD (Hiroshima, Japan). Synthetic peptides were lyophilized and stored at −20°C until use.

Preparation of fluorescent PBAN analogs
---------------------------------------

A 200-μl aliquot containing 250 μg Rhodamine Red succinimidyl ester (Life technologies, Tokyo, Japan) was added to a solution of 0.1 M sodium bicarbonate (pH 8.2) and 1.0 μmol synthetic peptide. The mixture was stirred overnight at room temperature and the conjugated peptide purified by HPLC under the same conditions as above. RR-C10 PBAN and RR--R^C2^X were stored at 4°C until use.

Preparation of stable PBANR--EGFP transformants
-----------------------------------------------

An expression plasmid encoding the BomPBANR fused with EGFP at its C-terminus was produced using a pIB/V5-His TOPO TA cloning kit (Life Technologies). Sf9 cells in IPL-41 insect cell medium (Life Technologies) supplemented with 10% fetal bovine serum (FBS) were transfected with the expression plasmid using Cellfectin (Life Technologies). Transfected Sf9 cells were selected using blasticidin S according to the manufacturer's procedures.

Confocal laser scanning microscope-based Ca^2+^ imaging assay
-------------------------------------------------------------

BomPBANR--EGFP stably expressing cells were harvested and incubated in 24 well glass bottom plate (AGC, Tokyo, Japan) at 28°C for 2 days with 10% FBS in IPL-41. On the day of experiment, cells were washed three times with IPL-41 and incubated in 250 μl of IPL-41 with 0.75 μl of Pluronic F-127 and 1 mM Fura Red AM (Life Technologies) for 30 min in the dark. After incubation, the cells were washed three times with IPL-41, and 300 μl IPL-41 was added to each well. The plate was left in the dark for 20 min to allow hydrolysis of the Fura Red AM ester bond. EGFP and Fura Red fluorescence were obtained on a FV-1000D confocal laser microscope (OLYMPUS, Tokyo, Japan) using 488 and 548 nm laser lines, respectively. To measure agonistic activity, fluorescence was monitored for 40 scans (1.08 s/scan), and a 100-μl peptide solution which were prepared to the concentration of 1, 10, 100, and 1000 nM was added to the well after 10 scans. For measuring antagonistic activity of R^C2^A and R^C2^D, the fluorescence was monitored for 50 scans. R^C2^A and R^C2^D solution (100 μl) was added to the well after 10 scans, and then 100 μl PBAN C10 was added after 25 scans. The Fura Red fluorescence was analyzed using the FV-1000D software "FluoView" (OLYMPUS). The data obtained were statistically analyzed using a Tukey--Kramer test. These experiments were performed with five replicates.

Confocal laser scanning microscope-based peptide binding assay
--------------------------------------------------------------

The binding ability of Rhodamine Red--R^C2^X peptides (X = Ala, Asp, Ser, and Aoc) to BomPBANR--EGFP was analyzed using a confocal laser scanning microscope. Sf9 cells adherently cultured on 35 mm glass bottom dishes (AGC, Tokyo, Japan) were transfected with 5 μg of expression plasmid containing BomPBANR--EGFP. Sixteen hours after transfection, the Sf9 cells were washed with 10% FBS/IPL-41 containing kanamycin at the final concentration of 200 μg/ml and incubated for 1 day at 28°C. On the day of the experiment, transfected cells were washed with serum free IPL-41 medium and incubated at 4°C for 15 min. To examine the binding of the labeled peptides to BomPBANR--EGFP, transfected cells were incubated in 500 μl IPL-41 containing each RR-peptide at the concentration of 100 nM at 4°C for 60 min in the dark, and then fixed with 4% formaldehyde/PBS. The fluorescence of BomPBANR--EGFP and RR-peptides were obtained on a FV-1000D confocal laser scanning microscope with 488 and 548 nm laser lines, respectively.
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